ArticleFrontiers in medicine2026
Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing global incidence of endometrial cancer (EC) underscores the urgent need for effective early detection. Noninvasive detection approaches, such as transvaginal ultrasonography (TVS), frequently exhibit low specificity, leading to a high rate of unnecessary invasive procedures. DNA methylation analysis has emerged as a promising noninvasive alternative. This study aimed to validate Methods: A prospective paired-samples study was conducted at Gansu Provincial Maternity and Child Care Hospital (July 2023-June 2024), including 226 eligible women. CBC and D&C samples were collected sequentially from each participant and tested for CDO1/CELF4 methylation, with diagnostic performance and consistency compared between sample types. Results: Among 226 participants, 31 were diagnosed with EIN or EC. Compared with conventional markers (cytology, endometrial thickness, and CA125 levels), individual Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.